Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.39−0.14 (-9.15%)
Close on Nov 18, 2026Market cap $270.38MP/E –Yield –
Altimmune free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Altimmune's free cash flow for the twelve months ending Jun 30, 2026 was -$76.56M. For fiscal 2025 it was -$67.55M. The highest annual figure on record is -$3.30M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$67.55M | – |
| FY2023 | Dec 31, 2023 | -$75.86M | – |
| FY2022 | Dec 31, 2022 | -$62.71M | – |
| FY2021 | Dec 31, 2021 | -$90.36M | – |
| FY2020 | Dec 31, 2020 | -$34.51M | – |
| FY2019 | Dec 31, 2019 | -$9.60M | – |
| FY2018 | Dec 31, 2018 | -$10.36M | – |
| FY2017 | Dec 31, 2017 | -$20.33M | – |
| FY2016 | Dec 31, 2016 | -$6.48M | – |
| FY2015 | Dec 31, 2015 | -$3.30M | – |
| FY2014 | Dec 31, 2014 | -$8.57M | – |
| FY2013 | Dec 31, 2013 | -$7.25M | – |
| FY2011 | Dec 31, 2011 | -$7.88M | – |
| FY2010 | Dec 31, 2010 | -$15.24M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.96M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.53M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.11M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.11M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.85M | – |
| Q2 FY2021 | Jun 30, 2021 | -$26.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.78M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.39M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.56M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.37M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.43M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.06M | -1718.0% |
| Q1 FY2019 | Mar 31, 2019 | -$2.11M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.16M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.18M | – |
| Q2 FY2018 | Jun 30, 2018 | $189.13K | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.21M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.26M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.85M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.38M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.50M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.99M | – |
See a number that looks wrong?